CClinicalTrials.gg
Status unknownNCT05395546Updated May 27, 2022

Digital Cognitive Behavioral Therapy (dCBT-I) for Maternal Insomnia

An interventional study of dCBT-I in Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I), sponsored by Women's Hospital School Of Medicine Zhejiang University. Status unknown. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-05-27.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Insomnia symptoms are common during pregnancy, especially in the second and third trimesters, which can reach more than 68%. Insomnia during pregnancy is not only associated with increased risk of preeclampsia, gestational diabetes, preterm labor, and cesarean section, but also increased postpartum poor sleep and postpartum depression. Cognitive behavioral therapy (CBT-I) and drug therapy for insomnia are the two main methods of insomnia treatment. Drug therapy is the more commonly used traditional treatment method, but there may be certain drug risks. Therefore, non-drug methods for Insomnia in pregnant women is much safer.

Cognitive-behavioral therapy for insomnia is a psychological therapy for insomnia. Compared with sedative-hypnotic drugs, its therapeutic effect is slow, but the curative effect is long-lasting, with less relapse after treatment and no invasive side effects. Multiple guidelines recommend it as first-line therapy for insomnia. And "Digital Cognitive Behavioral Therapy" (dCBT-I), is based on CBT-I, a therapy provided by the Internet and smartphones, which simulates face-to-face CBT-I in reality. It can provide more convenient medical services for the special group of pregnant women, improve sleep, improve mental symptoms, life treatment, and reduce the risk of adverse outcomes for mothers and children.

The Womens' Hospital, Zhejiang University School of Medicine is conducting a clinical study on "Digital Cognitive Behavioral Therapy (dCBT-I) for maternal Insomnia during pregnancy". The primary goal of this research project was to examine the efficacy of dCBT-I ("RuMian") in the treatment of maternal insomnia. "RuMian" is a fully automatic dCBT-I application developed in China, and subjects will use it for free.

02

Conditions studied

  • Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's planned enrollment of 200 is above the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 74 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-40 years old
  • 20-32 weeks of pregnancy, singleton pregnancy and regular obstetric examination at Zhejiang University Women's Hospital
  • There has been a high frequency of insomnia symptoms
  • According to the preliminary assessment by the project team, it meets the diagnostic criteria for insomnia
  • Possess a smart phone and can operate it proficiently, with normal reading and writing comprehension ability, clear consciousness, and able to cooperate with the research to complete the questionnaire independently.

Exclusion criteria

Exclusion Criteria:

  • Assess the risk of preterm birth and concurrent pregnancy-related diseases;
  • Completion of the 7-day sleep diary in the baseline period \< 4 days;
  • Combined with severe anxiety/depression;
  • Suicidal tendencies or severe mental illness (bipolar disorder, schizophrenia, paranoid psychosis, etc.);
  • Edinburgh Pregnancy Depression Scale (EPDS) total score ≥ 15;
  • Have drug dependence or have taken anti-anxiety, anti-depression, sedative or hypnotic drugs for mental diseases within the past 3 months;
  • Participated in interventions such as meditation courses, childbirth yoga or cognitive behavioral therapy in the past 1 year;
  • Complicated with serious physical diseases such as heart failure and tumor;
  • Combined with sleep disorders such as severe obstructive sleep apnea that require further evaluation and treatment;
  • There is alcohol and cigarette dependence;
  • Shift work;
  • Severe visual or hearing impairment and unable to use mobile phones normally;
  • Physical illness with unstable condition, or illness itself that may interfere with cognitive behavioral therapy for insomnia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    dCBT-I treatment group

    Other: dCBT-I

Interventions

  • OtherdCBT-I

    1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group 2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor 3. Scale assessment needs to be completed at the end of treatment 4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation

    Also known as: Device: smartphone

06

What researchers measure

Primary outcomes

  1. Change of "Insomnia Severity Index(ISI)"

    Insomnia Severity Index(ISI),the minimum and maximum values are 0 and 28, and higher scores mean a worse outcome.

    Time frame: From before treatment to the end of treatment (an average of 42 days)

Secondary outcomes

  1. Change of "Pittsburgh Sleep Quality Index(PSQI)"

    Pittsburgh Sleep Quality Index(PSQI),the minimum and maximum values are 0 and 21, and higher scores mean a worse outcome.

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  2. Change of "sleep onset latency(SOL)"

    simple questionnaire will be used to assess this outcome of sleep onset latency(SOL)

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  3. Change of "wake up after sleep onset(WASO)"

    simple questionnaire will be used to assess this outcome of WASO

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  4. Change of "sleep efficiency(SE)"

    combination of questionnaire and calculate will be used to assess this outcome of SE

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  5. Change of "Number of wake ups during the night"

    Number of wake ups during the night

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  6. Change of "total sleep time(TST)"

    total sleep time(TST)

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  7. Change of "Edinburgh Pregnancy Depression Scale(EPDS)"

    Edinburgh Pregnancy Depression Scale(EPDS),the minimum and maximum values are 0 and 30, and higher scores mean a worse outcome.

    Time frame: From before treatment to the end of treatment (an average of 42 days)

  8. Change of "Self-rating Anxiety Scale(SAS)"

    Self-rating Anxiety Scale(SAS), the minimum and maximum values are 25 and 100, and higher scores mean a worse outcome.

    Time frame: From before treatment to the end of treatment (an average of 42 days)

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05395546
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Jun 1, 2022 (estimated)
Primary completion
Jul 15, 2022 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
May 27, 2022

Study contacts

Zhaoxia Liang
Contact
xiaozaizai@zju.edu.cn
+860571-87061501

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion